Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous GVHD for Refractory Lymphoma
NCT00003414Phase 3Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Oct 1997
- Primary completion
- May 2004
- Modality
- Cytokines & Interferons, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of cyclosporine, interferon gamma-1b and aldesleukin in lymphoma and Hodgkin lymphoma (HL) (2 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Relapse rate for lymphoma after autologous transplant at 2 years. Started Oct 1997; status: completed.
02
Drugs
cyclosporineinterferon gamma-1baldesleukin
03
Conditions
lymphomaHodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00003414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003414.